Key Takeaways Shares of INVO Fertility (IVF) jumped approximately 145% on Monday following the release of its second-quarter fiscal 2026 results. The fertility services company reported dilut
Shares of INVO Fertility (IVF) skyrocketed 145% during Monday’s trading session after the company unveiled its second-quarter fiscal 2026 financial results, delivering a stunning earnings surprise that exceeded analyst projections.
Prior to the dramatic rally, shares closed at $0.97. The stock had experienced a devastating 74% decline year-to-date and a staggering 98% loss over the trailing twelve months, meaning Monday’s surge occurred from an extremely depressed valuation.
For the second quarter of fiscal 2026, the company posted diluted earnings per share of $0.35. This handily surpassed the analyst projection of -$0.70 by a substantial $1.05 margin. In comparison, the prior-year period showed adjusted EPS of -$364.23.
$IVF (INVO Fertility) Q2 2026 Results Revenue up 17%… clinic growth + acquisition drive, net income turns positive on one-time gain
KEY METRICS (Q2 2026)
Total Revenue: $2.18M (+17% YoY from $1.86M)
— Emmanuel – Big Tech & AI Investor (@EmmanuelInvest) August 17, 2026
Quarterly revenue registered between $2.17M and $2.18M. While this figure fell slightly below the $2.4M consensus forecast, it represented a 17% increase from the $1.86M generated in the comparable quarter of the previous year.
Trading activity reflected extraordinary investor interest. Over 55 million IVF shares were traded on Monday. Given the company’s three-month average daily volume of approximately 51,000 shares, Monday’s trading represented more than 1,000 times typical activity levels.
Chief Executive Officer Steve Shum identified several critical growth catalysts. Most significant was the complete quarterly contribution from Family Beginnings, a fertility clinic operation based in Indiana.
Additionally, INVO finalized the purchase of the remaining ownership interest in its fertility clinic located in Birmingham, Alabama during the reporting period.
The company’s clinic operations platform produced roughly $333,000 in Adjusted EBITDA prior to corporate overhead and public company costs during Q2. For the entire fiscal 2025 year, this metric reached $0.95 million.
INVO also emphasized research developments, noting five poster abstracts were showcased at the 2026 Midwest Reproductive Symposium International.
Management indicated the company remains actively pursuing acquisitions of additional cash-flow positive fertility clinics to expand its operational footprint.
INVO Fertility lacks conventional Wall Street analyst coverage. TipRanks’ AI-powered analyst Spark, which utilizes the OpenAI 5.2 model, assigns IVF stock a Neutral rating alongside a $0.94 price objective.
Spark identified “weak financial performance,” particularly “large losses and ongoing cash burn” as primary concerns supporting this neutral outlook.
InvestingPro assigns INVO Fertility a Financial Health rating of “fair performance.”
The company experienced both upward and downward EPS estimate revisions during the 90-day period preceding this earnings announcement.
Even after Monday’s substantial rally, IVF shares remain down 38% over the past three-month period and 98% over the trailing year.
The Q2 performance represents the company’s first positive EPS reading in recent memory, a dramatic reversal from the -$364.23 adjusted EPS reported during Q2 2025.
The post INVO Fertility (IVF) Stock Skyrockets 145% Following Stellar Q2 Earnings Performance appeared first on Blockonomi.
